Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma.

ABSTRACT: MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a cle

SUBMITTER: Zacarias-Fluck MF 

PROVIDER: S-EPMC10153459 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature